Home

Almak bitmiş tekrarlama puma biotechnology news servis Diğer gruplarla kalıcı olarak

Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results, Beats  Estimates By $0.11 EPS - Opera News
Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results, Beats Estimates By $0.11 EPS - Opera News

Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool

Where Will Puma Biotechnology Inc (PBYI) Stock Go Next After It Is Lower By  3.91% in a Week?
Where Will Puma Biotechnology Inc (PBYI) Stock Go Next After It Is Lower By 3.91% in a Week?

Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business

Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement  to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire

Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors  think so | FiercePharma
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma

Is Puma Biotechnology a Buy? | The Motley Fool
Is Puma Biotechnology a Buy? | The Motley Fool

PharmaShots - Incisive news in 3 shots on Twitter:
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ… https://t.co/sWLJCNJzQV"

HCW starts Puma Biotechnology at buy; PT $15 | BioTuesdays
HCW starts Puma Biotechnology at buy; PT $15 | BioTuesdays

Federal Jury Awards Puma Biotechnology Investors Damages in Securities  Class-Action Verdict | Los Angeles Business Journal
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict | Los Angeles Business Journal

Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha

PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug  Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer |  FDA Health News
PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News

Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual  Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha

Here's Why Puma Biotechnology Inc (NASDAQ:PBYI) Is Running Up - Market  Exclusive
Here's Why Puma Biotechnology Inc (NASDAQ:PBYI) Is Running Up - Market Exclusive

European Patent Board Rules in Favour of Puma Biotechnology - IP News Shots
European Patent Board Rules in Favour of Puma Biotechnology - IP News Shots

Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology - Crunchbase Company Profile & Funding

Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead?  | BioSpace
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace

Puma Biotechnology, Inc. Logo Vector - (.SVG + .PNG) - Tukuz.Com
Puma Biotechnology, Inc. Logo Vector - (.SVG + .PNG) - Tukuz.Com

Former Puma Biotech executive gets U.S. prison term for insider trading |  Reuters
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters

Video Puma Biotechnology Soars on Breast Cancer Drug Results - ABC News
Video Puma Biotechnology Soars on Breast Cancer Drug Results - ABC News

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology
Puma Biotechnology

Puma Biotechnology
Puma Biotechnology

Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet

Here's Why Puma Biotechnology Tumbled Today | The Motley Fool
Here's Why Puma Biotechnology Tumbled Today | The Motley Fool